Recursion Pharmaceuticals Inc (RXRX)
5.695
-0.06
(-0.96%)
USD |
NASDAQ |
Nov 22, 16:00
5.75
+0.06
(+0.97%)
After-Hours: 20:00
Recursion Pharmaceuticals Debt to Equity Ratio: 0.0548 for Sept. 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2024 | 0.0548 |
| June 30, 2024 | 0.0531 |
| March 31, 2024 | 0.0028 |
| December 31, 2023 | 0.0025 |
| September 30, 2023 | 0.0042 |
| June 30, 2023 | 0.0039 |
| March 31, 2023 | 0.0043 |
| December 31, 2022 | 0.0013 |
| Date | Value |
|---|---|
| September 30, 2022 | 0.0017 |
| June 30, 2022 | 0.0016 |
| March 31, 2022 | 0.0014 |
| December 31, 2021 | 0.0013 |
| September 30, 2021 | 0.0012 |
| June 30, 2021 | 0.0195 |
| March 31, 2021 | -0.0536 |
| December 31, 2020 | -0.0605 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-0.0605
Minimum
Dec 2020
0.0548
Maximum
Sep 2024
0.0025
Average
0.0021
Median
Debt to Equity Ratio Benchmarks
| Revance Therapeutics Inc | -2.645 |
| NovaBay Pharmaceuticals Inc | 0.0476 |
| Palatin Technologies Inc | -- |
| iBio Inc | -- |
| Theriva Biologics Inc | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 726.50M |
| Total Liabilities (Quarterly) | 201.94M |
| Shareholders Equity (Quarterly) | 524.56M |
| Current Ratio | 4.355 |
| Net Debt Paydown Yield | -0.29% |